IL-6 stimulates intestinal epithelial proliferation and repair after injury

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Kuhn, Kristine A ^a,b   Manieri, Nicholas A ^a   Liu, Ta Chiang ^a   Stappenbeck, Thaddeus S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; MESSENGER RNA; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL PROLIFERATION; CELL REGENERATION; CLINICAL ARTICLE; COLITIS; COLON INJURY; COLON PERFORATION; CONTROLLED STUDY; CRYPT CELL; CYTOKINE RESPONSE; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN SITU HYBRIDIZATION; INTESTINE EPITHELIUM; INTESTINE INJURY; INTESTINE PERFORATION; LYMPHOCYTE; MALE; MIDDLE AGED; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETROSPECTIVE STUDY; WOUND HEALING; ANIMAL; APOPTOSIS; BIOPSY; COLON; DISEASE MODEL; EPITHELIUM CELL; GENETICS; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; INJURIES; INTESTINE; INTESTINE MUCOSA; METABOLISM; PATHOLOGY; T LYMPHOCYTE;

BACTERIA (MICROORGANISMS); MURINAE;

ANIMALS; APOPTOSIS; BIOPSY; CELL PROLIFERATION; COLITIS; COLON; DISEASE MODELS, ANIMAL; EPITHELIAL CELLS; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-6; INTESTINAL MUCOSA; INTESTINES; MICE; T-LYMPHOCYTES; WOUND HEALING;

EID: 84918522920     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0114195     Document Type: Article

References (33)

1. Park H, Li Z, Yang XO, Chang SH, Nurieva R, et al. (2005) A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6: 1133-1141.
2. Langrish CL, Chen Y, Blumenschein WM, Mattson J, Basham B, et al. (2005) IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 201: 233-240.
3. Harrington LE, Hatton RD, Mangan PR, Turner H, Murphy TL, et al. (2005) Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 6: 1123-1132.
4. Dayer JM, Choy E (2010) Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology (Oxford) 49: 15-24.
5. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, et al. (2008) Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 371: 987-997.
6. Kremer JM, Blanco R, Brzosko M, Burgos-Vargas R, Halland AM, et al. (2011) Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structural joint damage at one year. Arthritis Rheum 63: 609-621.
7. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, et al. (2008) IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to antitumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 67: 1516-1523.
8. Gout T, Ostor AJ, Nisar MK (2011) Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review. Clin Rheumatol 30: 1471-1474.
9. Ito H, Takazoe M, Fukuda Y, Hibi T, Kusugami K, et al. (2004) A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn's disease. Gastroenterology 126: 989-996; discussion 947.
10. Waldner MJ, Neurath MF (2014) Master regulator of intestinal disease: IL-6 in chronic inflammation and cancer development. Semin Immunol 26: 75-79.
11. Mudter J, Neurath MF (2007) Il-6 signaling in inflammatory bowel disease: pathophysiological role and clinical relevance. Inflamm Bowel Dis 13: 1016-1023.
12. Reinisch W, Gasche C, Tillinger W, Wyatt J, Lichtenberger C, et al. (1999) Clinical relevance of serum interleukin-6 in Crohn's disease: single point measurements, therapy monitoring, and prediction of clinical relapse. Am J Gastroenterol 94: 2156-2164.
13. Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, Bennecke M, et al. (2009) gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 15: 91-102.
14. Grivennikov S, Karin E, Terzic J, Mucida D, Yu GY, et al. (2009) IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell 15: 103-113.
15. Dann SM, Spehlmann ME, Hammond DC, Iimura M, Hase K, et al. (2008) IL-6-dependent mucosal protection prevents establishment of a microbial niche for attaching/effacing lesion-forming enteric bacterial pathogens. J Immunol 180: 6816-6826.
16. Miyoshi H, Ajima R, Luo CT, Yamaguchi TP, Stappenbeck TS (2012) Wnt5a potentiates TGF-beta signaling to promote colonic crypt regeneration after tissue injury. Science 338: 108-113.
17. Kang SS, Bloom SM, Norian LA, Geske MJ, Flavell RA, et al. (2008) An antibiotic-responsive mouse model of fulminant ulcerative colitis. PLoS Med 5: e41.
18. Bloom S, Bijanki V, Nava G, Sun L, Malvin N, et al. (2011) Commensal Bacteroides species induce colitis in host-genotype-specific fashion in a mouse model of inflammatory bowel disease. Cell host & microbe 9: 390-793.
19. Starnes HF Jr, Pearce MK, Tewari A, Yim JH, Zou JC, et al. (1990) Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-alpha challenge in mice. J Immunol 145: 4185-4191.
20. Manieri NA, Drylewicz MR, Miyoshi H, Stappenbeck TS (2012) Igf2bp1 is required for full induction of Ptgs2 mRNA in colonic mesenchymal stem cells in mice. Gastroenterology 143: 110-121 e110.
21. Seno H, Miyoshi H, Brown SL, Geske MJ, Colonna M, et al. (2009) Efficient colonic mucosal wound repair requires Trem2 signaling. Proc Natl Acad Sci U S A 106: 256-261.
22. Matsumoto S, Hara T, Mitsuyama K, Yamamoto M, Tsuruta O, et al. (2010) Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model. J Immunol 184: 1543-1551.
23. Kitamura K, Nakamoto Y, Kaneko S, Mukaida N (2004) Pivotal roles of interleukin-6 in transmural inflammation in murine T cell transfer colitis. J Leukoc Biol 76: 1111-1117.
24. Becker C, Fantini MC, Schramm C, Lehr HA, Wirtz S, et al. (2004) TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 21: 491-501.
25. Chung YC, Chang YF (2003) Serum interleukin-6 levels reflect the disease status of colorectal cancer. J Surg Oncol 83: 222-226.
26. Galizia G, Orditura M, Romano C, Lieto E, Castellano P, et al. (2002) Prognostic significance of circulating IL-10 and IL-6 serum levels in colon cancer patients undergoing surgery. Clin Immunol 102: 169-178.
27. Schneider MR, Hoeflich A, Fischer JR, Wolf E, Sordat B, et al. (2000) Interleukin-6 stimulates clonogenic growth of primary and metastatic human colon carcinoma cells. Cancer Lett 151: 31-38.
28. Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, et al. (1994) Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature 368: 339-342.
29. Woodroofe C, Muller W, Ruther U (1992) Long-term consequences of interleukin-6 overexpression in transgenic mice. DNA Cell Biol 11: 587-592.
30. Kovalchuk AL, Kim JS, Park SS, Coleman AE, Ward JM, et al. (2002) IL-6 transgenic mouse model for extraosseous plasmacytoma. Proc Natl Acad Sci U S A 99: 1509-1514.
31. Suzuki Y, Saito H, Kasanuki J, Kishimoto T, Tamura Y, et al. (1990) Significant increase of interleukin 6 production in blood mononuclear leukocytes obtained from patients with active inflammatory bowel disease. Life Sci 47: 2193-2197.
32. Reinecker HC, Steffen M, Witthoeft T, Pflueger I, Schreiber S, et al. (1993) Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease. Clin Exp Immunol 94: 174-181.
33. Beagley KW, Fujihashi K, Lagoo AS, Lagoo-Deenadaylan S, Black CA, et al. (1995) Differences in intraepithelial lymphocyte T cell subsets isolated from murine small versus large intestine. J Immunol 154: 5611-5619.